Oxipit

Oxipit, now part of Sectra 

Radiology departments face rising imaging volumes with the same number of radiologists. Oxipit develops AI that takes routine work off the worklist, so radiologists can focus on the studies that need their judgment. 

Oxipit was founded in Lithuania in 2017 by specialists in medicine and data science. In 2019, the company received CE marking for ChestEye™, which detects 75 chest X-ray findings. In 2022, it launched ChestLink™, the first solution with CE Class IIb certification for autonomous chest X-ray analysis. In 2026, Oxipit extended its portfolio to musculoskeletal X-ray with MSK Eye™.   

In April 2026, Sectra completed its acquisition of Oxipit. The Oxipit team now operates as a dedicated AI development center within Sectra, and Sectra continues to develop ChestLink™.